Home › Endometrial Cancer › Alabama › Mobile
Endometrial Cancer clinical trials in Mobile, AL
4 studies for Endometrial Cancer are looking for participants at sites in and around Mobile (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of South Alabama Mitchell Cancer Institute, Mobile
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- USAH Mitchell Cancer Inst, Mobile
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Mobile
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Mobile
- Non-Small Cell Lung Cancer12 studies
- Heart Failure12 studies
- Breast Cancer8 studies
- Ovarian Cancer7 studies
- Lung Cancer7 studies
- Atrial Fibrillation6 studies
- Obesity6 studies
- Crohn's Disease6 studies
- Small Cell Lung Cancer6 studies
- Cancer (all types)6 studies
- Melanoma6 studies
- Type 2 Diabetes5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.